Agios Pharmaceuticals, Inc. Earnings

Agios Pharmaceuticals, Inc.’s revenue jumped 86.09% since last year same period to $19.97Mn in the Q4 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 55.02% jump in its revenue since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit fell -11.93% since last year same period to $-108.04Mn in the Q4 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated -4.45% fall in its net profits since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit margin jumped 39.85% since last year same period to -541.09% in the Q4 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 32.62% jump in its net profit margins since last 3-months.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.95 - a -2.09% fall from last quarter’s estimates.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -1.95.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) fell -6.32% since last year same period to -1.85 in the Q4 2025. This indicates that the Agios Pharmaceuticals, Inc. has generated -6.32% annual rate of fall in its earning per share (EPS) in the last 4 quarters.